Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Collegium Pharmaceutical, Inc.
COLL
NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·Mkt cap $1.2B
$37.03
▲ +3.23%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$29.19 - $50.79
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 17.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary abuse-deterrent technology platform reducing misuse potential
- FDA-approved portfolio addressing unmet needs in pain management
- Regulatory expertise and established relationships with healthcare providers
- Differentiated formulations in a market increasingly focused on opioid safety
Bear Case
1 risk
- Low volatility (beta 0.7).
Growth
Stable outlook
Increasing adoption of abuse-deterrent opioids by healthcare systems and insurers
Value
Deep value opportunity - significant discount to Large Cap Pharma peers
Momentum
Strong
+11.0% over 3m
Quality
Excellent
Exceptional business - top-tier fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying COLL right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 6, 2026
MAY 7, 2026
Reported EPS of $1.76 vs $1.52 consensus (+15.8% surprise). Revenue of $193.5M vs $184.5M expected (+4.9%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+15.8%
Next: May 6, 2026
Revenue trend · last 8Q
—
—
+22%
+23%
+29%
+31%
+13%
+9%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$145.3M
$159.3M
$181.9M
$177.8M
$188.0M
$209.4M
$205.4M
$193.5M
Margins · last 8Q
Gross
—
Operating
—
Profit
7.5%
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Mar 20, 2026